Compare PPIH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPIH | CNTX |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.3M | 283.9M |
| IPO Year | 1994 | 2021 |
| Metric | PPIH | CNTX |
|---|---|---|
| Price | $31.15 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $36.00 | $6.60 |
| AVG Volume (30 Days) | 77.7K | ★ 626.5K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.61 | 17.39 |
| EPS | ★ 2.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $9.33 | N/A |
| P/E Ratio | $15.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.22 | $0.56 |
| 52 Week High | $36.72 | $3.62 |
| Indicator | PPIH | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 32.45 |
| Support Level | $29.22 | $0.95 |
| Resistance Level | $33.42 | $2.00 |
| Average True Range (ATR) | 1.49 | 0.22 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 47.13 | 0.36 |
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, the Middle East, Europe, India, and other countries.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.